Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Merck"

194 News Found

BASF and Merck KGaA introduce a new standard for electronic exchange of quality and regulatory data
News | June 07, 2023

BASF and Merck KGaA introduce a new standard for electronic exchange of quality and regulatory data

The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information


Mixed prospects for Merck lawsuit against US federal government, says GlobalData
News | June 07, 2023

Mixed prospects for Merck lawsuit against US federal government, says GlobalData

The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past


Merck partners with California-based research group to study catalysis innovation through machine learning
News | June 02, 2023

Merck partners with California-based research group to study catalysis innovation through machine learning

Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques


Merck plans bioprocessing center in South Korea
News | May 05, 2023

Merck plans bioprocessing center in South Korea

The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.


Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline
News | April 17, 2023

Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline

Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology


Moderna and Merck announce an investigational individualized neoantigen therapy
Diagnostic Center | April 17, 2023

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients


FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric
Drug Approval | April 14, 2023

FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression


FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer
Drug Approval | April 04, 2023

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients


USFDA approves intramuscular administration for Merck’s MMRV family of vaccines
Drug Approval | March 07, 2023

USFDA approves intramuscular administration for Merck’s MMRV family of vaccines

With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly


Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
News | March 03, 2023

Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.